智通财经7月2日电，北陆药业(300016.SZ)公告称，公司股东王代雪计划通过询价转让方式转让737.83万 股，占公司总股本的1.49%。此次转让原因为自身资金需求，受让方需具备相应定价能力和风险承受能 力。转让价格下限为发送认购邀请书之日前20个交易日股票交易均价的70%。本次询价转让不通过集中 竞价交易方式或大宗交易方式进行，不属于通过二级市场减持。 北陆药业：股东王代雪拟询价转让737.83万股 占总股本1.49% ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-063 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 股东询价转让计划书 股东王代雪（以下简称"出让方"）保证向北京北陆药业股份有限公司（以 下简称"公司"或"北陆药业"）提供的信息内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 重要内容提示： 1 本次拟参与询价转让的股东为王代雪； 出让方拟转让股份的总数为 7,378,344 股，占北陆药业 2025 年 7 月 1 日 总股本的比例为 1.49%； 本次询价转让为非公开转让，不通过集中竞价交易方式或大宗交易方式 进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在 受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投 资者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 2 出让方委托中国国际金融股份有限公司（以下简称"中金公司"）组织实 施本次询价转让。截至 2025 年 7 月 ...

中国国际金融股份有限公司 关于北京北陆药业股份有限公司 股东向特定机构投资者询价转让股份 相关资格的核查意见 中国国际金融股份有限公司（以下简称"中金公司"）受北京北陆药业股份有限 公司（以下简称"北陆药业"）股东王代雪（以下简称"出让方"）委托，组织实施 本次北陆药业股东向特定机构投资者询价转让（以下简称"本次询价转让"）。 根据《上市公司股东减持股份管理暂行办法》《深圳证券交易所创业板股票上市 规则（2025 年修订）》《深圳证券交易所上市公司自律监管指引第 18 号——股东及 董事、高级管理人员减持股份（2025 年修订）》《深圳证券交易所上市公司自律监管 指引第 16 号——创业板上市公司股东询价和配售方式转让股份（2025 年修订）》 （以下简称"《指引第 16 号》"）等相关规定，中金公司对参与本次询价出让方的相 关资格进行了核查。 （一）核查过程 根据相关法规要求，中金公司已完成对出让方相关资格的核查工作，包括核查出 让方提供的身份证件、《承诺及声明函》等，并通过公开信息渠道检索等方式对出让 方资格进行核查，同时收集了相关核查底稿。 1 本次询价转让的委托情况、出让方相关资格的核查情况及核查意见 ...

中信建投：发行不超200亿元永续次级公司债券获批 7月2日晚，中信建投（601066）发布公告称，公司收到中国证监会批复，同意公司向专业投资者公开发 行面值总额不超过200亿元永续次级公司债券注册申请。该批复自同意注册之日起24个月内有效，公司 在注册有效期内可以分期发行永续次级公司债券。 蓝思科技：获中信银行9亿元贷款承诺用于股票回购 7月2日晚，蓝思科技（300433）发布公告称，公司收到中信银行股份有限公司长沙分行出具的《贷款承 诺函》，将为其提供不超过9亿元的贷款，专项用于支持公司回购股票。 资料显示，蓝思科技成立于2006年12月，主营业务是智能终端全产业链一站式精密制造解决方案。 所属行业：电子–消费电子–消费电子零部件及组装 华仁药业：全资子公司布美他尼原料药获批上市 7月2日晚，华仁药业（300110）发布公告称，公司收到国家药品监督管理局核准签发的布美他尼原料药 《化学原料药上市申请批准通知书》。布美他尼适用于治疗严重心力衰竭、高血压急症及严重钠潴留 等，其利尿作用强，对肾功能影响小。 资料显示，华仁药业成立于1998年5月，是一家集研发、生产、销售为一体的,以肾科、呼吸科、精麻 科、治疗性 ...

Group 1: Company Announcements - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [1] - Saisir reported June sales of 46,086 new energy vehicles, a year-on-year increase of 4.44%, with a total of 172,100 units sold in the first half of the year, down 14.35% year-on-year [1] - Hangzhou High-tech announced a change in controlling shareholder to Jirong Weiye, with stock resuming trading on July 2, 2025 [1] Group 2: Financial Performance - Guomai Technology expects a net profit of 125 million to 156 million yuan for the first half of 2025, a year-on-year increase of 60.52% to 100.33% [2] - Kid King anticipates a net profit of 120 million to 160 million yuan for the first half of 2025, representing a year-on-year growth of 50% to 100% [2] - Mould Technology received a project from a well-known North American electric vehicle company, with expected total sales of 1.236 billion yuan over five years [3] Group 3: Regulatory and Compliance - *ST Yuancheng is under investigation by the China Securities Regulatory Commission for suspected false disclosures in financial reports [4] - The company received a notice of investigation on July 1, 2025, which may lead to significant penalties and potential delisting [4] Group 4: Market Activity - Changcheng Military Industry's stock has experienced significant volatility, with a cumulative price deviation exceeding 20% over three trading days, indicating potential irrational speculation [5] - Anglikang has only one innovative drug project, ALK-N001, currently in Phase I clinical trials, highlighting the long and uncertain nature of drug development [6] Group 5: Sales and Contracts - Beiqi Blue Valley's subsidiary reported a 139.73% year-on-year increase in sales for the first half of the year [7] - Dong'an Power's engine sales in June increased by 82.79% year-on-year [7] - Pudong Construction's subsidiary won multiple major projects with a total bid amount of 1.964 billion yuan [7]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

股票代码：300016 股票简称：北陆药业 公告编号：2025-062 债券代码：123082 债券简称：北陆转债 申请事项：境内生产化学原料药上市申请 北京北陆药业股份有限公司 关于控股子公司海昌药业碘普罗胺化学原料药获批上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，北京北陆药业股份有限公司（以下简称"公司"或"北陆药业"） 控股子公司浙江海昌药业股份有限公司（以下简称"海昌药业"）收到国家药 品监督管理局核准签发的碘普罗胺《化学原料药上市申请批准通知书》。现将 相关情况公告如下： 一、药品的基本情况 化学原料药通用名称：碘普罗胺 英文名/拉丁名：Iopromide 化学原料药注册标准编号：YBY66212025 有效期：18 个月 包装规格：25.0kg/桶 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册。 生产企业名称：浙江海昌药业股份有限公司 1 生产企业地址：浙江省玉环市沙门镇滨港工业城长顺路 36 号 登记号：Y20240000048 受理号：CYHS2460107 通知书编 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-061 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于 2025 年第二季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300016 证券简称：北陆药业 经中国证券监督管理委员会证监许可〔2020〕2810号文同意注册，公司 于2020年12月7日向不特定对象发行500万张可转换公司债券，每张面值100 元，发行总额50,000.00万元。 债券代码：123082 债券简称：北陆转债 转股价格：人民币7.02元/股 转股时间：2021 年 6 月 11 日至 2026 年 12 月 6 日 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，北京北陆药业股份 有限公司（以下简称"公司"）现将 2025 年第二季度可转换公司债券（以下 简称"可转债"）转股及公司股份变动的情况公告如下： 一、可转债发行上市概况 经深圳证券交易所同意，公司50,000 ...

Group 1 - The company participated in a centralized procurement program in Xinjiang, aiming to select its gadobutrol injection and gadopentetate dimeglumine injection [1] - The proposed price for gadopentetate dimeglumine injection (15ml:7.04g) is 80.26 yuan per unit, while gadobutrol injection (15ml:7.935g) is priced at 185.69 yuan per unit [1] - For the year 2024, the sales revenue from gadopentetate dimeglumine injection is projected to be 236 million yuan, accounting for 24.01% of the company's total revenue for the period [1]

股票代码：300016 股票简称：北陆药业 公告编号：2025-060 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于钆贝葡胺注射剂、钆喷酸葡胺注射剂拟中选新疆维吾尔自治区 二十六省联盟药品集中带量采购的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，北京北陆药业股份有限公司（以下简称"公司"）参加了新疆维吾 尔自治区二十六省联盟药品集中带量采购工作，根据新疆维吾尔自治区医疗保 障局发布的《二十六省联盟药品集中带量采购综合评审拟中选结果公示》显示， 公司钆贝葡胺注射剂、钆喷酸葡胺注射剂拟中选本次集中带量采购。现将相关 情况公告如下： | 拟中选企 | 药品通用名 | 剂型 | 适应症 | 规格 | 计价 | 拟中选价 | | --- | --- | --- | --- | --- | --- | --- | | 业 | | | | | 单位 | 格（元） | | 北京北陆药 | 钆贝葡胺 | 注射剂 | 核磁共振 | 15ml:7.935g 钆贝葡胺(相当于钆 | 支 | 185.69 | | 业股份有限 | | | 增 ...